Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$37.68 USD
-0.15 (-0.40%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $37.70 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Xenon Pharmaceuticals Inc. [XENE]
Reports for Purchase
Showing records 1 - 20 ( 125 total )
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
The Year Of Execution Continues As XENE Keeps Advancing Pipeline
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
X-TOLE?ing The Virtues Of Clinical Trial Execution; X-TOLE2 On Track
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
X-NOVA Results- Concept Proven, Expending Potential for XEN1101. Multiple Go-Forword Options.
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: Epilepsy KOL Check - AES Wrap and Thoughts Into 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
When A Miss Isn''t A Miss: X-NOVA Results Bolster Differentiation
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for XENE 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Getting Past The NOVA -- X-TOLE-2 On Track To Enroll In 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
MDD Webinar Takeaways: Event Offers Context Into Upcoming X-NOVA Readout
Provider: Wedbush Securities Inc.
Analyst: CHICO L